<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422016000400005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Asma en pediatría]]></article-title>
<article-title xml:lang="en"><![CDATA[Asthma in pediatrics]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarrete-Rodríguez]]></surname>
<given-names><![CDATA[Elsy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sienra-Monge]]></surname>
<given-names><![CDATA[Juan José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pozo-Beltrán]]></surname>
<given-names><![CDATA[César Fireth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil de México "Federico Gómez" Servicio de Alergia e Inmunología. Clínica ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Infantil de México "Federico Gómez" Subdirección Pediatría Ambulatoria ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2016</year>
</pub-date>
<volume>59</volume>
<numero>4</numero>
<fpage>5</fpage>
<lpage>15</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422016000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422016000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422016000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El asma es un trastorno inflamatorio crónico de las vías respiratorias, que lleva a episodios recurrentes de sibilancias, disnea, sensación de opresión torácica y tos. Actualmente se considera como un problema de salud pública en diversos países, y en México su prevalencia se estima en un 8%. Se puede dividir en 2 grandes grupos: asma alérgica, mediada por inmunoglobulina E (IgE) y desencadenada principalmente por aeroalérgenos, y asma no alérgica, cuyos factores etiológicos son las infecciones, irritantes, etc. Los principales componentes a identificar antes de iniciar el tratamiento son: la gravedad, el control, la respuesta a medicamentos y la incapacidad provocada. El tratamiento farmacológico se basa en medicamentos rescatadores, que se utilizan en situaciones agudas, y controladores administrados de forma continua y encaminados a disminuir la inflamación y los síntomas a largo plazo. Las decisiones de la terapéutica instalada deben de ser dinámicas, pasando de una etapa a otra, de acuerdo con los síntomas. En el caso de que exista algún alérgeno como desencadenante de los cuadros, se recomienda utilizar la inmunoterapia para reducir la respuesta alérgica, principalmente en los casos en los que el alérgeno no pueda evitarse.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Asthma is a chronic inflammatory disorder of the airways, which leads to recurrent episodes of wheezing, shortness of breath, chest tightness and/or cough; now is considered a public health problem in many countries, in Mexico the prevalence is estimated in 8%. Asthma can be divided in two groups: allergic asthma, IgE-mediated and primarily triggered by airborne allergens and no allergic asthma whose etiological factors are infections, irritants, etc. The main components to be identified before starting treatment are: severity, control, response to drugs and disability. Medications to treat asthma can be classified as relievers, drugs used in acute situations or controllers, medications taken daily on a long-term basis to keep asthma under clinical control chiefly through their anti-inflammatory effects. The therapeutic decisions must be installed dynamic, moving from one to another stage, according to the symptoms. In case an allergen is the trigger of the symptoms, the recommended treatment is immunotherapy in order to reduce the allergic response especially in cases where the allergen can not be avoided.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Asma]]></kwd>
<kwd lng="es"><![CDATA[sibilancias]]></kwd>
<kwd lng="es"><![CDATA[alergia]]></kwd>
<kwd lng="es"><![CDATA[inmunoterapia]]></kwd>
<kwd lng="en"><![CDATA[Asthma]]></kwd>
<kwd lng="en"><![CDATA[wheezing]]></kwd>
<kwd lng="en"><![CDATA[allergy]]></kwd>
<kwd lng="en"><![CDATA[immunotherapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="">
<source><![CDATA[Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>National Asthma Education and Prevention Program</collab>
<article-title xml:lang=""><![CDATA[Expert Panel Report 3 (EPR-3) Guidelines for the diagnosis and managment of asthma summary report 2007]]></article-title>
<source><![CDATA[J Allergy Clinimmunol]]></source>
<year>2007</year>
<volume>120</volume>
<numero>5 Suppl</numero>
<issue>5 Suppl</issue>
<page-range>S94-138</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>ISAAC Stering Committee</collab>
<article-title xml:lang=""><![CDATA[Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema ISAAC]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>1998</year>
<volume>351</volume>
<page-range>1225-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Beasley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crane]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Foliaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weiland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global variation in the prevalence and severity of asthma symptoms Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC)]]></article-title>
<collab>International Study of Asthma and Allergies in Childhood Phase Three Study Group</collab>
<source><![CDATA[Thorax]]></source>
<year>2009</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>476-83</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del-Rio-Navarro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rio-Chivardi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Berber]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sienra-Monge]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas-Vargas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Baeza-Bacab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asthma prevalence in children living in north Mexico City and a comparison with other Latin American cities and world regions]]></article-title>
<source><![CDATA[Allergy Asthma Proc.]]></source>
<year>2006</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>334-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asher]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Montefort]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Björkstén]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Strachan]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Weiland]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood ISAAC Phases One and Three repeat multicountry cross-sectional surveys]]></article-title>
<collab>ISAAC Phase Three Study Group et al</collab>
<source><![CDATA[Lancet]]></source>
<year>2006</year>
<volume>368</volume>
<numero>9537</numero>
<issue>9537</issue>
<page-range>733-43</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shore]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and asthma possible mechanisms]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2008</year>
<volume>121</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1087-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larenas Linnemann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Arias Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guidos Fogelbach]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Cid del Prado]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergens used in skin tests in Mexico]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2009</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heinzerling]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bachert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burney]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical guide to skin prick tests in allergy to aeroallergens]]></article-title>
<collab>Global Allergy and Asthma European NetworkAllergic Rhinitis and its Impact on Asthma</collab>
<source><![CDATA[Allergy]]></source>
<year>2012</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sigurs]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bjarnason]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sigurbergsson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kjellman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2000</year>
<volume>161</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1501-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dezateux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stocks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dundas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impaired airway function and wheezing in infancy the influence of maternal smoking and a genetic predisposition to asthma]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1999</year>
<volume>159</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>403-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uzzaman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chapter 28: Classification of hypersensitivity reactions]]></article-title>
<source><![CDATA[Allergy Asthma Proc.]]></source>
<year>2012</year>
<volume>33</volume>
<numero>^sl 1</numero>
<issue>^sl 1</issue>
<supplement>l 1</supplement>
<page-range>S96-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="">
<source><![CDATA[From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bisgaard]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-acting beta(2)-agonists in management of childhood asthma A critical review of the literature]]></article-title>
<source><![CDATA[Pediatr Pulmonol]]></source>
<year>2000</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>221-34</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salpeter]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ormiston]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Salpeter]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis respiratory tolerance to regular beta2-agonist use in patients with asthma]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2004</year>
<volume>140</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>802-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhaled short acting beta2-agonist use in chronic asthma regular versus as needed treatment]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2003</year>
<numero>2</numero>
<issue>2</issue>
<page-range>CD001285</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosas-Vargas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[del Rio-Chivardi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Hidalgo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[del Rio-Navarro]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Sienra-Monge]]></surname>
<given-names><![CDATA[JJL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tipos y características de los inhaladores para el Manejo de asma]]></article-title>
<source><![CDATA[Bol Med Hosp Infant Mex.]]></source>
<year>2005</year>
<volume>113</volume>
<page-range>11-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cates]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Crilly]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cámaras espaciadoras versus nebulizadores para el tratamiento del asma aguda con betaagonistas]]></article-title>
<source><![CDATA[La Biblioteca Cochrane Plus]]></source>
<year>2008</year>
<numero>3</numero>
<issue>3</issue>
<publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo Laita]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[De Benito Fernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Escribano Montaner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Benítez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García de la Rubia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garde Garde]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement on the management of paediatric asthma. Update 2007. First Spanish Consensus for the Management of Asthma in Paediatrics]]></article-title>
<source><![CDATA[Allergol Immunopathol (Madr)]]></source>
<year>2008</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-52</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iramain]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[López-Herce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children]]></article-title>
<source><![CDATA[J Asthma]]></source>
<year>2011</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>298-303</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plotnick]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ducharme]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2000</year>
<numero>4</numero>
<issue>4</issue>
<page-range>CD000060</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bateman]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Hurd]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Drazen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global strategy for asthma management and prevention GINA executive summary]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2008</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>143-78</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amirav]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Newhouse]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Minocchieri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Rodriguez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Schüepp]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors that affect the efficacy of inhaled corticosteroids for infants and young children]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2010</year>
<volume>125</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1206-11</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bacharier]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Boner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsen]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Eigenmann]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Frischer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Götz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of asthma in childhood a PRACTALL consensus report]]></article-title>
<collab>European Pediatric Asthma Group</collab>
<source><![CDATA[Allergy]]></source>
<year>2008</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-34</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bisgaard]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zielen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Garcia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Gilles]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Menten]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2005</year>
<volume>171</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>315-22</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Musgrave]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Shepstone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hillyer]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Sims]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leukotriene antagonists as first-line or add-on asthma-controller therapy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1695-707</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anselmo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pediatric asthma controller therapy]]></article-title>
<source><![CDATA[Paediatr Drugs]]></source>
<year>2011</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<collab>Grupo de trabajo "Consenso Mexicano de Asma"</collab>
<article-title xml:lang=""><![CDATA[Guía Mexicana de asma]]></article-title>
<source><![CDATA[Neumología y cirugía de tórax]]></source>
<year>2009</year>
<volume>68</volume>
<numero>^ssuplemento</numero>
<issue>^ssuplemento</issue>
<supplement>suplemento</supplement>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Greening]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single maintenance and reliever therapy (SMART) of asthma a critical appraisal]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>2010</year>
<volume>65</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>747-52</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ni Chroinin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Greenstone]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lasserson]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ducharme]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2009</year>
<numero>4</numero>
<issue>4</issue>
<page-range>CD005307</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lockey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malling]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergen immunotherapy therapeutic vaccines for allergic diseases. A WHO position paper]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>1998</year>
<volume>102</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>558-62</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Penagos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Durham]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases]]></article-title>
<source><![CDATA[Clin Allergy Immunol]]></source>
<year>2008</year>
<volume>21</volume>
<page-range>359-75</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compalati]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Penagos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tarantini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Passalacqua]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Specific immunotherapy for respiratory allergy state of the art according to current meta-analyses]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2009</year>
<volume>102</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bridges]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kulus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Berhane]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vidaurre]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2009</year>
<volume>124</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1210-6</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Lanier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Buhl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Holgate]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and tolerability of omalizumab Clin Exp]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2009</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>788-97</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neffen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Rodriguez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma a systematic review]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2011</year>
<volume>139</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>28-35</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gergen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Gern]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1005-15</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
